FDA Approves Pfizer's Tukysa for First-Line HER2+ Breast Cancer

The U.S. Food and Drug Administration approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer.

The approval moves the oral therapy into an earlier treatment setting for patients who have completed induction therapy, backed by phase 3 trial results demonstrating an 8.6-month improvement in progression-free survival compared to a control regimen.

"Since its first approval in 2020, Tukysa has become an important treatment for patients with second-line HER2+ metastatic breast cancer," said Aamir Malik, executive vice president and chief U.S. commercial officer of Pfizer. "Today's FDA approval marks the next chapter for Tukysa, bringing it into the front-line maintenance setting and offering patients a chemotherapy-free option that can help delay disease progression after initial treatment."

Clinical Trial Findings and Survival Data

The regulatory decision is based on data from the HER2CLIMB-05 phase 3 clinical trial, which evaluated the efficacy of the tucatinib combination regimen. According to the study findings, median progression-free survival reached 24.9 months for patients receiving Tukysa, compared to 16.3 months for those receiving a placebo, yielding a hazard ratio of 0.64 with a statistically significant P-value of less than 0.0001.

"The treatment environment for HER2+ metastatic breast cancer has evolved significantly over the past decade, but many patients still experience disease progression despite initial benefit from therapy," said Erika Hamilton, M.D., principal investigator of HER2CLIMB-05 and director of breast cancer research at Sarah Cannon Research Institute. "The HER2CLIMB-05 findings support TUKYSA plus trastuzumab and pertuzumab as a chemotherapy-free maintenance strategy that allows us to target HER2-positive tumors from multiple angles and can help prolong disease control."

Safety Profile and Boxed Warnings

While clinical trials demonstrated prolonged disease control, the regulatory filing notes notable safety considerations. Serious hepatotoxicity occurred in 3.9% of patients in the trial, which included one fatal case of drug-induced liver injury.

Adverse liver events led to treatment discontinuation in 8% of patients. Consequently, the product label carries a boxed warning regarding severe hepatotoxicity, requiring clinicians to monitor liver enzyme levels regularly during the course of maintenance therapy.